Thiogenesis Therapeutics, Corp. (TTI:TSXV) closed at $0.650 on November 12, 2026, unchanged on the day. The stock trades 9.7% below its 52-week high of $0.720 and 47.7% above its 52-week low of $0.440. Over the past year, it lost 7.1%. Thiogenesis Therapeutics, Corp. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, TTI closed higher on 65 days (26%). Its best day was October 22, 2026 (+21.65%) and its worst was March 11, 2026 (-15.25%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 14 times.
Thiogenesis Therapeutics Corp is an early stage biotech company. It is developing novel drug formulations that act as precursors to cysteamine, which is a small aminothiol compound that is endogenous in humans in small quantities.
Find more stocks like TTI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.